# Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

> **NCT00094549** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 500 (—)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** olanzapine
- **DRUG:** divalproex sodium
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00094549
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 500 (—)
- **Last updated:** 2007-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094549, "Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT00094549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*